We’ll kick off this week’s roundup with two more FDA approvals of drugs brought to market by Big Pharma companies but originated in biotech labs. Biotechs have come to represent a big part of medicines that come to market, especially when... Read more »
With barely a whisper, Seattle biotech Allozyne has been broken up for parts, with most of its assets sold off earlier this summer to a previous licensing partner, Xconomy has learned.
The buyer was MedImmune, the biotech division of the multinational... Read more »
Investor purse strings loosened to fund North Carolina companies to the tune of $266 million in the first half of 2014, up more than 31 percent compared to the same period last year, according to a new report. But perhaps more... Read more »
Tokai Pharmaceuticals may be trying to break into an increasingly crowded field of prostate cancer drugs, but Wall Street investors clearly like its chances to make an impact.
Cambridge, MA-based Tokai priced its IPO at $15 per share, the top... Read more »
Third Rock Ventures started up MyoKardia in 2012 around the idea of making genetically targeted drugs for certain forms of heart disease. Two years and $38 million in venture funding into the effort, French pharmaceutical giant Sanofi is buying into the... Read more »
It wasn’t too long ago that Proteon Therapeutics looked to be a piece of Novartis’ portfolio. That deal flamed out, however, leading the Waltham, MA-based biotech to retrench, find some new investors, and—as the company as just disclosed today—chart a course... Read more »
Here’s a quick rundown of recent news from Wisconsin’s technology and innovation community:
—A federal judge rejected a request by Milwaukee taxi groups to halt a new city law that lifts the cap on taxi permits and provides a pathway to... Read more »
It’s back to work, back to school, and back to the grind in biotech. One local company inched towards a potential FDA approval, yet its stock is down more than 10 percent. Another biotech came under fire for a big price... Read more »
With a pharma partnership already in hand and big biotech names on board, the Cambridge, MA-based startup Scholar Rock today announced a $20 million Series A round of funding.
With the cash, the company will continue its pursuit of antibody therapies... Read more »
Here is a quick roundup of recent news from Colorado startups and tech companies, including news about Ball Aerospace’s new laser-communications satellites, Zayo’s deal to wire the NBA, and the upcoming Apex Awards.
Space lasers: Ball Aerospace & Technologies announced this... Read more »